Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma

BACKGROUND: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAF(V600)-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. METHODS: Pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Cancer
Prif Awduron: Dréno, Brigitte, Ascierto, Paolo A, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Bartley, Karen, Karagiannis, Thomas, Chang, Ilsung, Rooney, Isabelle, Koralek, Daniel O, Larkin, James, McArthur, Grant A, Ribas, Antoni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2018
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5877437/
https://ncbi.nlm.nih.gov/pubmed/29438370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.488
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg